QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: jpet.105.097733v1 317/2/901    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tang, L. Articles by Wang, Z. J. Search for Related Content PubMed PubMed Citation Articles by Tang, L. Articles by Wang, Z. J.

NEUROPHARMACOLOGY

Reversal of Morphine Antinociceptive Tolerance and Dependence by the Acute Supraspinal Inhibition of Ca²⁺/Calmodulin-Dependent Protein Kinase II

Department of Biopharmaceutical Sciences (L.T., P.K.S., L.X.W., Z.J.W.), and Cancer Center (Z.J.W.), University of Illinois, Chicago, Illinois; and Feinberg School of Medicine, Northwestern University, Chicago, Illinois (L.X.W.)

Previous studies have suggested that Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) can modulate opioid tolerance and dependence via its action on learning and memory. In this study, we examined whether CaMKII could directly regulate opioid tolerance and dependence. CaMKII activity was increased after the treatment with morphine (100 mg/kg s.c. or 75 mg s.c. of morphine/pellet/mouse); the effect exhibited a temporal correction with the development of opioid tolerance and dependence. In mice treated with morphine (100 mg/kg s.c.), morphine tolerance and dependence developed in 2 to 6 h. An acute supraspinal administration of KN93 [2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine)], a CaMKII inhibitor, was able to dose-dependently reverse the already-established antinociceptive tolerance to morphine (p < 0.001 for 15-30 nmol; not significant for 5 nmol). KN92 [2-[N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine] (30 nmol i.c.v.), a kinase-inactive analog of KN93, did not affect opioid tolerance. Neither KN92 nor KN93 affected basal nociception or acute morphine antinociception (1-10 nmol i.c.v.). Likewise, dependence on morphine was abolished by the acute administration of KN93, but not KN92, in a dose-dependent manner. Pretreatment of mice with KN93 also prevented the development of morphine tolerance and dependence. The effect of acute CaMKII inhibition was not limited to the particular experimental model, because KN93 also acutely reversed the established opioid tolerance and dependence in mice treated with morphine (75 mg/pellet/mouse s.c.) for 6 days. Taken together, these data strongly support the hypothesis that CaMKII can act as a key and direct factor in promoting opioid tolerance and dependence. Identifying such a direct mechanism may be useful for designing pharmacological treatments for these conditions.

Address correspondence to: Dr. Zaijie Jim Wang, Department of Biopharmaceutical Sciences, University of Illinois, 833 South Woods Street, Chicago, IL 60612. E-mail: zjwang{at}uic.edu

This article has been cited by other articles:

				F. Luo, C. Yang, Y. Chen, P. Shukla, L. Tang, L. X. Wang, and Z. J. Wang Reversal of Chronic Inflammatory Pain by Acute Inhibition of Ca2+/Calmodulin-Dependent Protein Kinase II J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 267 - 275. [Abstract] [Full Text] [PDF]

				L. Tang, Y. Chen, Z. Chen, P. M. Blumberg, A. P. Kozikowski, and Z. J. Wang Antinociceptive Pharmacology of N-(4-Chlorobenzyl)-N'-(4-hydroxy-3-iodo-5-methoxybenzyl) Thiourea, a High-Affinity Competitive Antagonist of the Transient Receptor Potential Vanilloid 1 Receptor J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 791 - 798. [Abstract] [Full Text] [PDF]

				J. R. Parkitna, I. Obara, A. Wawrzczak-Bargiela, W. Makuch, B. Przewlocka, and R. Przewlocki Effects of Glycogen Synthase Kinase 3beta and Cyclin-Dependent Kinase 5 Inhibitors on Morphine-Induced Analgesia and Tolerance in Rats J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 832 - 839. [Abstract] [Full Text] [PDF]

				S. Li, M. L. Lee, M. R. Bruchas, G. C. Chan, D. R. Storm, and C. Chavkin Calmodulin-Stimulated Adenylyl Cyclase Gene Deletion Affects Morphine Responses Mol. Pharmacol., November 1, 2006; 70(5): 1742 - 1749. [Abstract] [Full Text] [PDF]